Article

Large-Scale Study Shows Dramatic Decline in Mortality Rates for ARDS

Author(s):

The largest study performed to date of mortality trends in patients with acute respiratory distress syndrome (ARDS) shows that the rate of mortality dropped significantly over a 16-year period.

The largest study performed to date of mortality trends in patients with acute respiratory distress syndrome (ARDS) shows that the rate of mortality dropped significantly over a 16-year period. Advances in critical care medicine are seen as a direct cause of the decline. The study abstract was released October 21 in the Online First section of the journal CHEST and will be presented at CHEST 2014, the annual meeting of the American College of Chest Physicians in Austin, Texas held October 25-30.

Researchers at Rutgers Robert Wood Johnson Medical School, Staten Island University Hospital, the University of Pittsburgh Medical Center, and Government Medical College obtained data from the National Inpatient Sample (NIS) database, the largest inpatient health-care database in the United States, encompassing data from approximately 8 million hospital stays per year. Out of this database, they were able to identify over 174,000 patients who had ARDS.

The study showed that there was a striking decrease in mortality rates, from 46.8% in 1996 to 32.2% in 2011, a 14.6% reduction. Surprisingly, from the years 2000 to 2005 alone there was an 8.9% absolute reduction in mortality rates.

According to Jared Radbel, MD, “While we cannot prove causation for the decreased mortality, we believe that collaborative advances in critical care medicine contributed to the overall decline. We assert that the sudden and sharp decrease in mortality from 2000-2005 can be attributed to the practice of low tidal volume ventilation.”

Source: American College of Chest Physicians

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
How to Manage Aspirin-Exacerbated Respiratory Disease
© 2024 MJH Life Sciences

All rights reserved.